The European Central Bank convenes this week with a resurgent euro presenting a fresh dilemma, threatening to dampen inflation and undermine the export engine of the eurozone's largest economies just as recovery gains momentum.
With luxury hotels fully booked, affluent Super Bowl attendees are turning to off-market mega-mansions in the Bay Area, driving last-minute rental prices to unprecedented heights of up to half a million dollars for a single week.
Asset managers ramped up bearish bets against the U.S. dollar to their highest level in months, only to be blindsided by a sudden rally fueled by speculation that former Fed Governor Kevin Warsh is President Trump's pick to lead the central bank.
Singapore's Venture Corporation (SGX:V03) has delivered a robust 38% total shareholder return over the past year, buoyed by dividends. However, a closer look reveals declining earnings and revenue, raising questions about the sustainability of its recent market favor and its longer-term trajectory.
As a significant equity rotation takes hold in early 2026, shifting focus from growth to value, dividend-focused ETFs are emerging as key beneficiaries for investors seeking yield and stability.
Vital Farms (VITL) is drawing renewed investor attention following a series of earnings estimate upgrades and consistent beats. Despite a recent pullback, analysts see significant upside, citing strong brand positioning and operational scale. However, underlying challenges in retail volumes and cash flow present a more complex picture for the pasture-raised egg producer.
Driven by a global wave of semiconductor investment, Applied Materials (AMAT) has received a series of analyst upgrades. Mizuho and Deutsche Bank are among those highlighting the company's strategic position to benefit from expansive fab construction in the U.S., Taiwan, and Japan, and its key role in next-generation chip technologies.
AI infrastructure provider CoreWeave finds itself at a critical juncture, buoyed by a deepened $2 billion partnership with chip giant Nvidia while simultaneously defending against securities lawsuits. Investors are weighing the promise of accelerated growth against allegations of misleading disclosures, creating a volatile mix for the high-flying stock.
Idorsia's exclusive licensing agreement with EMS to commercialize insomnia drug QUVIVIQ across Latin America marks a key step in its global expansion. The deal, involving $20 million in milestones and royalties, arrives as long-term data for its Fabry disease candidate lucerastat puts the spotlight on the company's broader late-stage pipeline and persistent financial pressures.
As China's pork industry grapples with overcapacity and falling prices, a growing appetite for premium, flavorful black pork among the middle class is offering a lifeline to farmers and reshaping market strategies.
The Malaysian healthcare provider KPJ Healthcare Berhad is demonstrating a strengthened capacity for profitable reinvestment, with its return on capital employed rising to 11% alongside significant capital expansion, pointing to a robust operational model.
Japan's manufacturing activity expanded at its fastest pace since mid-2022 in January, a key private survey shows, driven by robust domestic and international orders. While the sector's revival is clear, rising input costs and inflation concerns temper the optimism.
As Smurfit Westrock navigates the complex post-merger landscape, its share price tells a conflicted story. While recent gains hint at optimism, a deeper look reveals a stock trading at a significant discount to some intrinsic value models, even as its P/E ratio suggests a premium. The market appears to be weighing integration execution risks against long-term synergy potential.
Shares of Ethos Technologies have slumped 10.7% year-to-date, trading around $15.05. A detailed valuation analysis reveals a stark contradiction: while a discounted cash flow model suggests massive undervaluation, its price-to-earnings ratio paints a picture of overvaluation. This divergence highlights the critical debate among investors about the insurer's true worth and future trajectory.
Broadcom secures a pivotal, multi-year agreement to supply custom AI chips to OpenAI, cementing its role as a key silicon partner for tech giants. However, the semiconductor leader must simultaneously navigate customer churn from its VMware unit and heightened regulatory scrutiny, presenting a complex risk-reward profile for investors.
As CME Group's stock rides a wave of strong derivatives trading activity, a deep dive into its valuation metrics suggests the market may be getting ahead of itself. With shares up over 24% in the past year, we examine whether the current price truly reflects the exchange giant's underlying value.
While Arbor Realty Trust offers shareholders clarity on favorable tax treatment for 2025 dividends, analysts remain focused on a deteriorating earnings outlook and a 'Strong Sell' rating, casting doubt on the stock's near-term prospects.
AXIS Capital Holdings (AXS) shares have surged 15% over the past year, closing at $103.18 and reigniting discussions about its valuation. Analysts see a potential upside to $121, but the market weighs risks from cyber claims and social inflation.
BeOne Medicines (ONC) presents a complex picture for investors, with recent short-term volatility contrasting sharply with strong long-term returns. As the stock trades around $340, analysts debate whether its current price fully reflects the ambitious growth narrative in its oncology pipeline.
First American Financial Corp. announces the retirement of director Martha Wyrsch while reaffirming its quarterly dividend, signaling stability in shareholder returns during a period of governance change. The company's stock performance and capital allocation strategy remain in focus for investors.
